FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors
| Autor: | L Aggelou, Theologia Sarafidou, Constantina A. Sarri, Yiannis Vasilopoulos, Dimitrios Sotiriadis, Efterpi Zafiriou, A V Roussaki-Schulze, Aikaterini Patsatsi, Aikaterini Kyriakou, D Papadopoulou, E Mendrinou, Zissis Mamuris |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Adult Male Genotype Pharmacogenomic Variants Population Anti-Inflammatory Agents Drug Resistance Disease Pharmacology Polymorphism Single Nucleotide Etanercept 03 medical and health sciences 0302 clinical medicine Psoriasis Genetics medicine Humans education Retrospective Studies 030203 arthritis & rheumatology education.field_of_study business.industry Tumor Necrosis Factor-alpha Receptors IgG FCGR3A Middle Aged medicine.disease Immunoglobulin Fc Fragments Pharmacogenomic Testing 030104 developmental biology Phenotype Treatment Outcome Pharmacogenetics Rheumatoid arthritis Immunology Molecular Medicine Female business medicine.drug |
| Zdroj: | The pharmacogenomics journal. 17(3) |
| ISSN: | 1473-1150 |
| Popis: | Psoriasis is a multifactorial skin disease affecting ~2% of world's population, causing a dramatic decrease in patients' quality of life and a significant increase in health-care expenses. Biological agents such as the anti-TNFα ones had an enormous impact in patients' therapy; however, a significant proportion of them do not respond well, an outcome attributed mainly to genetic factors. Recently, in a large European cohort of rheumatoid arthritis patients we have shown association with variation in the receptors that correspond to the Fc portion of the biological agents. As both diseases share common immunological fingerprints, we examined the hypothesis that they share common pharmacogenetic markers. Analysis of FCGR2A-H131R and FCGR3A-V158F polymorphisms in 100 psoriasis patients showed association only with respect to FCGR3A-V158F and response to etanercept (P=0.018). Interestingly, no association was found between FCGR2A-H131R and response to anti-TNFα therapy (P=0.882). This study suggests a role for FCGR3A-V158F polymorphism unique for psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink